G-Quadruplex Modulation Alters TDP-43 Aggregation and Toxicity

Study Background and Research Question

Trans-active response DNA-binding protein 43 kDa (TDP-43) is a multifunctional RNA-binding protein central to RNA metabolism and regulation in eukaryotic cells. Pathological aggregation of TDP-43 is a defining feature in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration, two major neurodegenerative disorders. While TDP-43 inclusions are observed in the vast majority of ALS cases, the mechanistic basis for its aggregation remains poorly understood. Previous studies have shown that TDP-43 interacts with a variety of RNA structures, including GU-rich sequences and G-quadruplexes (G4s)—non-canonical four-stranded helices prevalent in guanine-rich genomic regions. However, the functional significance of this interaction, and whether G-quadruplexes influence TDP-43 behavior in cells, had not been thoroughly explored. Oldani et al. address this gap by investigating how RNA G-quadruplexes modulate TDP-43 condensation, distribution, and toxicity in vitro and in cellular models (Oldani et al., 2025).

Key Innovation from the Reference Study

The principal innovation of Oldani et al.’s work lies in directly linking RNA G-quadruplexes to the physical and toxicological behavior of TDP-43 in vitro and across multiple cellular systems. The study demonstrates that G-quadruplexes not only bind TDP-43, but also actively modulate its aggregation and cytotoxicity. Moreover, the use of G-quadruplex binding ligands to stabilize these structures is shown to alleviate TDP-43 condensation and toxicity, providing a mechanistic rationale for targeting RNA secondary structures in neurodegenerative disease research.

Methods and Experimental Design Insights

Oldani et al. employed a combination of biochemical, genetic, and imaging approaches to dissect the relationship between G-quadruplexes and TDP-43. Key methodological components included:

• In vitro aggregation assays using recombinant eGFP-TDP-43 protein in the presence of synthetic DNA G-quadruplexes, to assess direct modulation of aggregation behavior.
• Cellular models across multiple systems: Saccharomyces cerevisiae (yeast), HEK293T human embryonic kidney cells, and NSC-34 motor-neuron-like cells, each engineered to express exogenous or endogenous TDP-43.
• Treatment of cells with synthetic G-quadruplexes and G-quadruplex stabilizing ligands, followed by monitoring of TDP-43 localization, aggregation, and cytotoxicity through fluorescence microscopy and viability assays.
• Stress induction (proteasomal inhibition, oxidative stress) to simulate conditions relevant to neurodegenerative disease pathophysiology and observe the effect of G-quadruplex modulation on TDP-43 behavior under these conditions.

Protocol Parameters

• G-quadruplex ligand exposure: Typically 0–40 μM, with exposure times of approximately 72 hours, as is common in G-quadruplex modulation workflows (see product information).
• Stress induction: Proteasomal or oxidative stress applied to HEK293T and NSC-34 cells to enhance TDP-43 aggregation, mimicking disease-like conditions.
• Microscopy analysis: Co-localization of G-quadruplexes and TDP-43 aggregates evaluated by fluorescence imaging in fixed and live cell models.
• Cell viability assays: Quantification of cytotoxicity following TDP-43 overexpression and G-quadruplex modulation.

Core Findings and Why They Matter

The study reveals several critical findings (Oldani et al., 2025):

• G-quadruplexes modulate TDP-43 aggregation in vitro: Addition of synthetic G4 oligonucleotides alters the aggregation kinetics and morphology of recombinant TDP-43, indicating a direct biophysical influence.
• G-quadruplexes co-localize with TDP-43 aggregates under stress: In both yeast and mammalian cell models, G4s are observed to accumulate alongside pathological TDP-43 condensates, particularly under proteotoxic stress.
• Exogenous G-quadruplexes increase cellular tolerance to TDP-43: In yeast, treatment with synthetic G4s leads to higher TDP-43 accumulation without a proportional increase in cytotoxicity, suggesting a chaperoning or sequestration effect.
• G-quadruplex binding ligands alleviate TDP-43 toxicity: Stabilization of G4s through small molecule ligands reduces TDP-43 condensation and cytotoxicity in HEK293T and NSC-34 cells, supporting the therapeutic potential of G4-targeting strategies.

These observations substantiate the concept that RNA secondary structures, specifically G-quadruplexes, can be leveraged to modulate protein aggregation phenomena central to neurodegenerative pathologies. The finding that G-quadruplex stabilization reduces TDP-43 toxicity suggests a mechanistic pathway for intervention in ALS and related disorders.

Comparison with Existing Internal Articles

Several internal articles corroborate and extend the implications of Oldani et al.’s study. For instance, the overview "G-Quadruplex Modulation of TDP-43 Aggregation and Toxicity" summarizes the evidence for G-quadruplexes as modulators of TDP-43 cytotoxicity and aggregation, echoing the reference study’s mechanistic findings. Similarly, "Pyridostatin: Advancing G-Quadruplex Biology and Disease Research" explores how G-quadruplex stabilizers, such as Pyridostatin TFA, empower researchers to interrogate both DNA and RNA G-quadruplex biology across cancer and neurodegeneration models. Notably, these resources highlight the growing recognition of G-quadruplex modulation as a bridge between cancer cell growth inhibitor research and the study of protein aggregation in neurodegeneration. The article "Pyridostatin in G-Quadruplex and TDP-43 Research: New Frontiers" further discusses the unique role of synthetic G-quadruplex stabilizers in extending research beyond telomere biology into novel domains, including ALS models.

Limitations and Transferability

While the study by Oldani et al. provides robust evidence for the modulation of TDP-43 by RNA G-quadruplexes, several limitations merit consideration. First, although multiple cell types were used, the majority of experiments were performed in overexpression models, which may not fully recapitulate endogenous TDP-43 dynamics observed in human pathology. Second, the translation of findings from yeast and transformed cell lines to primary neurons or in vivo ALS models remains to be established. Third, the specificity of G-quadruplex ligands—such as those structurally related to Pyridostatin—toward RNA versus DNA G-quadruplexes in the context of TDP-43 aggregation was not dissected in detail. Thus, while the mechanistic insights are compelling, further research is necessary to validate these findings in disease-relevant systems and to assess the selectivity and safety of G-quadruplex stabilization as a therapeutic approach.

Why this cross-domain matters, maturity, and limitations

The connection between G-quadruplex biology—traditionally associated with telomere function and cancer—and neurodegenerative disease mechanisms is a significant conceptual advance. Targeting G-quadruplexes with small molecules has long been explored in anticancer drug development, particularly as cancer cell growth inhibitors and telomere dysfunction inducers. This study demonstrates that similar approaches may be repurposed to address protein aggregation in ALS, suggesting that tools and workflows developed for DNA secondary structure research are directly transferable to neurodegeneration models. However, the maturity of this cross-domain application is still at the proof-of-concept stage, and further validation in neuronal and animal models is needed before clinical translation can be considered.

Research Support Resources

Researchers interested in exploring G-quadruplex stabilization in the context of TDP-43 or other aggregation-prone proteins can leverage well-characterized compounds such as Pyridostatin (SKU A3742, typically used as its TFA salt) to design and optimize experimental protocols. Pyridostatin is widely used in telomere biology research, DNA secondary structure research, and studies of G-quadruplex-mediated protein aggregation. For optimal results, follow established concentration and storage guidelines as detailed in the product information. APExBIO provides high-purity Pyridostatin suitable for in vitro and cellular G-quadruplex modulation workflows.